{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-000953","form_type":"8-K","ticker":"CTOR","cik":"0001851484","company_name":"CITIUS ONCOLOGY, INC.","filed_at":"2025-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.303734+00:00","generated_at":"2026-05-28T11:26:43.979991+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Citius Oncology retains Jefferies to explore strategic alternatives including sale or licensing","bullets":["Jefferies LLC appointed as exclusive financial advisor to assist in evaluating strategic alternatives.","Alternatives under consideration include partnerships, joint ventures, mergers, acquisitions, and licensing.","Company is preparing to launch LYMPHIR, FDA-approved for relapsed/refractory Stage I-III cutaneous T-cell lymphoma.","No timeline set; no assurance that a transaction will result from the review process."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-000953","json":"https://secwatch.observer/filing/0001213900-25-000953.json","markdown":"https://secwatch.observer/filing/0001213900-25-000953.md","text":"https://secwatch.observer/filing/0001213900-25-000953.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1851484/000121390025000953/0001213900-25-000953-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1851484/000121390025000953/ea0226665-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T11:26:43.979991+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}